1
|
Düğeroğlu H, Özgenoğlu M. Thyroid function among women with gestational trophoblastic diseases. A cross-sectional study. SAO PAULO MED J 2019; 137:278-283. [PMID: 31411244 PMCID: PMC9744006 DOI: 10.1590/1516-3180.2018.0481090519] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Accepted: 05/09/2019] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Gestational trophoblastic diseases (GTDs) are treatable rare tumors with wide distribution. The estimated incidence of GTDs varies dramatically between different regions globally. In early pregnancy, there may be high human chorionic gonadotropin (HCG) concentrations, normal or slightly increased free T4 (fT4) and subnormal thyroid-stimulating hormone (TSH), causing hyperthyroidism ranging from subclinical to severe. Beta-HCG causes thyrotoxicosis through thyroid stimulation in patients with trophoblastic tumors. OBJECTIVE To assess thyroid function among patients diagnosed with complete or partial hydatidiform mole, within the GTD spectrum. DESIGN AND SETTING Cross-sectional study based on patients' medical records at Van University Hospital, Van, Turkey. METHODS 50 patients monitored due to diagnoses of hydatidiform mole were included and were examined regarding thyroid function. Thyroid gland size and volume were measured using thyroid ultrasonography. Beta-HCG, TSH, fT4, free T3 (fT3), total T4 (TT4), total T3 (TT3), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG) and thyroglobulin levels were measured. RESULTS Among these patients, 15 (30%) were diagnosed with complete hydatidiform mole and 35 (70%) with partial hydatidiform mole, according to pathology results. Those with complete hydatidiform mole were older (P = 0.003), with higher number of pregnancies (P = 0.032), lower TSH level (P = 0.011) and higher fT4 and TT4 levels (P = 0.04; P = 0.028), compared with partial hydatidiform mole patients. CONCLUSION In hydatidiform mole patients, thyroid disease severity increases with age, parity, beta-HCG level and mole size. However, prospective multicenter studies on this topic are needed, with larger numbers of patients and closer monitoring.
Collapse
Affiliation(s)
- Harun Düğeroğlu
- MD. Assistant Professor, Department of Internal Medicine, Ordu Üniversitesi Tıp Fakültesi, Ordu, Turkey. Formerly at Van Yüzüncü Yıl Üniversitesi.
| | - Murat Özgenoğlu
- MD. Specialist Doctor, Internal Medicine Clinic, Ödemiş Devlet Hastanesi, İzmir, Turkey. Formerly at Van Yüzüncü Yıl Üniversitesi.
| |
Collapse
|
2
|
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018; 143 Suppl 2:79-85. [PMID: 30306586 DOI: 10.1002/ijgo.12615] [Citation(s) in RCA: 212] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum of premalignant to malignant disorders. Changes in epidemiology of GTD have been noted in various countries. In addition to histology, molecular genetic studies can help in the diagnostic pathway. Earlier detection of molar pregnancy by ultrasound has resulted in changes in clinical presentation and decreased morbidity from uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) is essential for early diagnosis of gestational trophoblastic neoplasia (GTN). The duration of hCG monitoring varies depending on histology type and regression rate. Low-risk GTN (FIGO Stages I-III: score <7) is treated with single-agent chemotherapy but may require additional agents; although scores 5-6 are associated with more drug resistance, overall survival approaches 100%. High-risk GTN (FIGO Stages II-III: score >7 and Stage IV) is treated with multiple agent chemotherapy, with or without adjuvant surgery for excision of resistant foci of disease or radiotherapy for brain metastases, achieving a survival rate of approximately 90%. Gentle induction chemotherapy helps reduce early deaths in patients with extensive tumor burden, but late mortality still occurs from recurrent resistant tumors.
Collapse
Affiliation(s)
- Hextan Y S Ngan
- Department of Obstetrics and Gynecology, Queen Mary Hospital, University of Hong Kong, Hong Kong, China
| | - Michael J Seckl
- Departments of Histopathology and Medical Oncology, Charing Cross Trophoblastic Disease Center, Charing Cross Campus of Imperial College London, London, UK
| | - Ross S Berkowitz
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Yang Xiang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - François Golfier
- Department of Obstetrics and Gynecology, French Trophoblastic Disease Reference Centre, Lyon University Hospital, Claude Bernard Lyon 1 University, Lyon, France
| | - Paradan K Sekharan
- Department of Obstetrics and Gynecology, Institute of Maternal and Child Health, Medical College, Calicut, India
| | - John R Lurain
- John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Leon Massuger
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands
| |
Collapse
|
3
|
Nguyen NMP, Ge ZJ, Reddy R, Fahiminiya S, Sauthier P, Bagga R, Sahin FI, Mahadevan S, Osmond M, Breguet M, Rahimi K, Lapensee L, Hovanes K, Srinivasan R, Van den Veyver IB, Sahoo T, Ao A, Majewski J, Taketo T, Slim R. Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles. Am J Hum Genet 2018; 103:740-751. [PMID: 30388401 DOI: 10.1016/j.ajhg.2018.10.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 10/03/2018] [Indexed: 11/17/2022] Open
Abstract
Androgenetic complete hydatidiform moles are human pregnancies with no embryos and affect 1 in every 1,400 pregnancies. They have mostly androgenetic monospermic genomes with all the chromosomes originating from a haploid sperm and no maternal chromosomes. Androgenetic complete hydatidiform moles were described in 1977, but how they occur has remained an open question. We identified bi-allelic deleterious mutations in MEI1, TOP6BL/C11orf80, and REC114, with roles in meiotic double-strand breaks formation in women with recurrent androgenetic complete hydatidiform moles. We investigated the occurrence of androgenesis in Mei1-deficient female mice and discovered that 8% of their oocytes lose all their chromosomes by extruding them with the spindles into the first polar body. We demonstrate that Mei1-/- oocytes are capable of fertilization and 5% produce androgenetic zygotes. Thus, we uncover a meiotic abnormality in mammals and a mechanism for the genesis of androgenetic zygotes that is the extrusion of all maternal chromosomes and their spindles into the first polar body.
Collapse
Affiliation(s)
| | - Zhao-Jia Ge
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada
| | - Ramesh Reddy
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada
| | - Somayyeh Fahiminiya
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Genome Québec Innovation Center, Montréal, QC H3A 0G1, Canada
| | - Philippe Sauthier
- Department of Obstetrics and Gynecology, Gynecologic Oncology Division, Centre Hospitalier de l'Université de Montréal, Réseau des Maladies Trophoblastiques du Québec, Montréal, QC H2X 0C1, Canada
| | - Rashmi Bagga
- Department of Obstetrics & Gynecology, Post Graduate Institute of Medical, Education and Research, PGIMER, Chandigarh 160012, India
| | - Feride Iffet Sahin
- Department of Medical Genetics, Faculty of Medicine, Baskent University, 06810 Ankara, Turkey
| | - Sangeetha Mahadevan
- Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Matthew Osmond
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Genome Québec Innovation Center, Montréal, QC H3A 0G1, Canada
| | - Magali Breguet
- Department of Obstetrics and Gynecology, Gynecologic Oncology Division, Centre Hospitalier de l'Université de Montréal, Réseau des Maladies Trophoblastiques du Québec, Montréal, QC H2X 0C1, Canada
| | - Kurosh Rahimi
- Department of Pathology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0C1, Canada
| | - Louise Lapensee
- Ovo Clinic, Montréal, QC H4P 2S4, Canada; Department of Obstetrics and Gynecology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2X 0C1, Canada
| | | | - Radhika Srinivasan
- Cytology & Gynecological Pathology, Post Graduate Institute of Medical Education and Research PGIMER, Chandigarh 160012, India
| | | | | | - Asangla Ao
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Department of Obstetrics and Gynecology, McGill University Health Centre, Montréal, QC H4A 3J1, Canada
| | - Jacek Majewski
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Genome Québec Innovation Center, Montréal, QC H3A 0G1, Canada
| | - Teruko Taketo
- Department of Obstetrics and Gynecology, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Department of Surgery, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Department of Biology, McGill University, Montréal, QC H3A 0G4, Canada
| | - Rima Slim
- Department of Human Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Department of Obstetrics and Gynecology, McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
| |
Collapse
|
4
|
Lazrak I, Ihssane H, Babahabib MA, Kouach J, El Ochi MR, Moussaoui MD, Dehayni M. [Partial invasive and metastatic hydatidiform mole: report of a case]. Pan Afr Med J 2014; 19:175. [PMID: 25815096 PMCID: PMC4366128 DOI: 10.11604/pamj.2014.19.175.5487] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 10/12/2014] [Indexed: 11/11/2022] Open
Abstract
Depuis plusieurs années, la môle hydatiforme partielle(MHP) a été considérée comme une entité bénigne qui ne nécessite pas une surveillance stricte comme celle de la môle complète(MC), mais l'apparition de quelques cas sporadiques de transformation de la môle partielle en maladie trophoblastique persistante que ça soit une môle invasive ou choriocarcinome ou voire même une tumeur du site d'implantation placentaire; a remis en question cette stratégie. A travers une observation d'une môle partielle invasive métastatique, et à travers une revue de la littérature, on a essayé d'appuyer cette conduite qui considère la môle partielle comme une pathologie potentiellement grave nécessitant une prise en charge adéquate et une surveillance assez rigoureuse.
Collapse
Affiliation(s)
- Ikram Lazrak
- Service de Gynécologie Obstétrique de l'Hôpital Militaire Med V de Rabat, Rabat, Maroc
| | - Hakimi Ihssane
- Service de Gynécologie Obstétrique de l'Hôpital Militaire Med V de Rabat, Rabat, Maroc
| | | | - Jaouad Kouach
- Service de Gynécologie Obstétrique de l'Hôpital Militaire Med V de Rabat, Rabat, Maroc
| | - Mohamed Reda El Ochi
- Service d'Anatomo-Pathologie de l'Hôpital Militaire Med V de Rabat, Rabat, Maroc
| | | | - Mohamed Dehayni
- Service de Gynécologie Obstétrique de l'Hôpital Militaire Med V de Rabat, Rabat, Maroc
| |
Collapse
|
5
|
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol 2009; 112:654-62. [DOI: 10.1016/j.ygyno.2008.09.005] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 09/03/2008] [Accepted: 09/05/2008] [Indexed: 10/21/2022]
|
6
|
Plasma homocysteine, vitamin B12 and folate levels in hydatidiform moles and histopathological subtypes. Arch Gynecol Obstet 2008; 278:531-4. [DOI: 10.1007/s00404-008-0637-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2007] [Accepted: 03/17/2008] [Indexed: 10/22/2022]
|
7
|
Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO. Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study. Gynecol Oncol 2006; 103:81-6. [PMID: 16516953 DOI: 10.1016/j.ygyno.2006.01.042] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2005] [Revised: 01/15/2006] [Accepted: 01/20/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE Hispanics are the fastest growing minority group in the United States. Few reports have described gestational trophoblastic disease (GTD) in this population. The purpose of this study was to determine the incidence of GTD at our public hospital which primarily serves the Hispanic population. METHODS All women diagnosed with GTD (partial and complete hydatidiform mole, choriocarcinoma) between 1983 and 2004 were identified from the institutional tumor registry, surgical pathology reports and hospital ICD-9 codes. Clinical data were retrospectively extracted from medical records. The live birth denominator was tabulated over the same interval of time by retrieving labor and delivery statistics and sorting by race. RESULTS GTD was diagnosed in 596 patients over a 21-year study interval encompassing 289,897 live births. The overall incidence of GTD was 2.06/1000 live births. Hispanic women had a higher incidence compared to Blacks (2.38 vs. 1.34; P < 0.001), but not Whites (2.00; P = 0.17). The 416 Hispanic women were diagnosed with GTD at an earlier gestational age in the latter part of this study (12.3 vs. 16.2 weeks; P < 0.001). Hispanics were more likely to have a partial hydatidiform mole compared to Blacks (29% vs. 13%; P < 0.001) and Whites (18%; P = 0.04). Choriocarcinomas occurred least commonly in Hispanic patients (1 per 35,000 live births). Teenage Hispanic women were the only ethnic age group with a higher risk of developing GTD (odds ratio = 1.6, 95% confidence interval: 1.1, 2.2). CONCLUSION Hispanic women had the highest incidence of GTD in this hospital-based study, were diagnosed at an earlier gestational age in the last decade and more frequently were diagnosed with partial moles.
Collapse
Affiliation(s)
- Richard D Drake
- Southwestern Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
| | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- Harriet O Smith
- Department of Obstetrics and Gynecology, University of New Mexico Health Science Center, Albuquerque, New Mexico, USA.
| |
Collapse
|
9
|
Perrotta S, Nobili B, Rossi F, Di Pinto D, Cucciolla V, Borriello A, Oliva A, Della Ragione F. Vitamin A and infancy. Biochemical, functional, and clinical aspects. VITAMINS AND HORMONES 2003; 66:457-591. [PMID: 12852263 DOI: 10.1016/s0083-6729(03)01013-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Vitamin A is a very intriguing natural compound. The molecule not only has a complex array of physiological functions, but also represents the precursor of promising and powerful new pharmacological agents. Although several aspects of human retinol metabolism, including absorption and tissue delivery, have been clarified, the type and amounts of vitamin A derivatives that are intracellularly produced remain quite elusive. In addition, their precise function and targets still need to be identified. Retinoic acids, undoubtedly, play a major role in explaining activities of retinol, but, recently, a large number of physiological functions have been attributed to different retinoids and to vitamin A itself. One of the primary roles this vitamin plays is in embryogenesis. Almost all steps in organogenesis are controlled by retinoic acids, thus suggesting that retinol is necessary for proper development of embryonic tissues. These considerations point to the dramatic importance of a sufficient intake of vitamin A and explain the consequences if intake of retinol is deficient. However, hypervitaminosis A also has a number of remarkable negative consequences, which, in same cases, could be fatal. Thus, the use of large doses of retinol in the treatment of some human diseases and the use of megavitamin therapy for certain chronic disorders as well as the growing tendency toward vitamin faddism should alert physicians to the possibility of vitamin overdose.
Collapse
Affiliation(s)
- Silverio Perrotta
- Department of Pediatric, Medical School, Second University of Naples, Naples, Italy
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
OBJECTIVES To review the incidence, etiology, diagnosis, treatment, and nursing implications of the uncommon gynecologic malignancies of vulvar carcinoma, vaginal carcinoma, sex cord-stromal tumors of the ovary, and gestational trophoblastic tumors. DATA SOURCES Research studies, review articles, medical and nursing textbooks. CONCLUSIONS Vulvar and vaginal cancers, sex cord-stromal tumors of the ovary, and gestational trophoblastic tumors are rare malignancies constituting less than 5% of all malignant diagnoses. If detected early these malignancies have a high possibility of cure. IMPLICATIONS FOR NURSING PRACTICE Nurses play an important role in the education of women and patients to the signs and symptoms of gynecologic malignancies, the disease process, treatment options, follow-up care, and resources available to these women.
Collapse
Affiliation(s)
- Amber Door
- Gynecologic Oncology of West Michigan, 1000 East Paris, Suite 242, Grand Rapids, MI 49546, USA
| |
Collapse
|
11
|
Parazzini F, Cipriani S, Mangili G, Garavaglia E, Guarnerio P, Ricci E, Benzi G, Salerio B, Polverino G, La Vecchia C. Oral contraceptives and risk of gestational trophoblastic disease. Contraception 2002; 65:425-7. [PMID: 12127642 DOI: 10.1016/s0010-7824(02)00293-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Clinical reports suggested that the use of oral contraceptives (OC) after a molar pregnancy may increase the risk of persistent throphoblastic disease. However, few epidemiologic studies have analyzed the effect of OC use on the risk of developing gestational trophoblastic disease (GTD). To give further information, we have analyzed data from a case-control study on risk factors for GTD. Cases were 268 women with a histologically confirmed diagnosis of complete or partial mole referred to the participating Trophoblastic Disease Centers. A total of 268 subjects were interviewed; 79 cases were classified as partial and 159 as complete mole. Controls were randomly selected women who gave birth to healthy infants at term on randomly selected days in the same network of hospitals in which cases had been identified. A total of 104 cases and 130 controls reported ever OC use, and the corresponding odds ratio (OR) was 1.5 (95% CI, 1.1-2.1). The risk of GTD increases with duration of OC use: the OR was 1.7 (95% CI 1.2-2.6) for ever-users reporting >or=12 months of use. No consistent pattern of risk was observed with time since last OC use. We have analyzed separately the association between OC use and risk of complete and partial moles: no statistically significant difference emerged, but the OR for partial moles was higher (OR 3.0, 95% CI 1.6-8.4) than for complete mole (OR 1.0, 95% CI 1.8). In conclusion, we observed a weak association between OC use and GTD; such a weak association could be explained by factors other than causality.
Collapse
Affiliation(s)
- Fabio Parazzini
- Prima Clinica Ostetrico Ginecologica, Università di Milano, Milano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Most of the functions of vitamin A are mediated through the binding of retinoic acid to specific nuclear receptors that regulate genomic expression. Recent experimental work in transgenic mice showed clearly that normal embryonic development depends on the correct spatial and temporal expression of the receptors in the differentiating cells and on the binding of specific forms of retinoic acid. This implies that the parent compound, vitamin A, is available in adequate forms and quantities. Excessive dietary intake of vitamin A has been associated with teratogenicity in humans in <20 reported cases over 30 y. However, caution must be exercised to avoid unnecessary supplementation of women of childbearing age. Hypovitaminosis A affects millions of women and children worldwide. The main consequence of a poor vitamin A supply during pregnancy is a low vitamin A status at birth and in the next few months. Vitamin A deficiency is strongly associated with depressed immune function and higher morbidity and mortality due to infectious diseases such as diarrhea, measles, and respiratory infections. Vitamin A deficiency is often associated with an increased mother-to-child transmission of HIV-1. The initiation of vitamin A supplementation should be carefully examined in each case according to the risk-to-benefit ratio. The final decision should take into account the estimated vitamin A status of the woman, the availability of vitamin A-rich foods in her diet, and whether supplementation can be supervised.
Collapse
Affiliation(s)
- V Azaïs-Braesco
- INRA, Human Nutrition and Food Safety Scientific Division, the Metabolic Diseases and Micronutrients Unit, Vitamin Research Group, Paris, France.
| | | |
Collapse
|
13
|
Palmer JR, Driscoll SG, Rosenberg L, Berkowitz RS, Lurain JR, Soper J, Twiggs LB, Gershenson DM, Kohorn EI, Berman M, Shapiro S, Rao RS. Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst 1999; 91:635-40. [PMID: 10203284 DOI: 10.1093/jnci/91.7.635] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Gestational trophoblastic disease refers to a spectrum of rare benign and malignant gynecologic disorders whose pathogenesis is not well understood. Recent studies from China and the United States have raised the hypothesis that long-term use of oral contraceptives before conception may increase the risk of gestational trophoblastic tumors. A multicenter case-control study of gestational trophoblastic tumors was undertaken to test this hypothesis. METHODS Telephone interviews were conducted with 235 case patients, including 50 with gestational choriocarcinoma, and 413 control subjects matched on recentness of pregnancy, age at pregnancy, and area of residence. Relative risks (odds ratios) were computed by conditional logistic regression. Reported P values are two-sided. RESULTS The relative risk estimate for ever having used oral contraceptives before the index pregnancy was 1.9 (95% confidence interval [CI] = 1.2-3.0), and the risk increased with duration of use (P for trend = .05). The estimate was highest for women who used oral contraceptives during the cycle in which they became pregnant (relative risk = 4.0; 95% CI=1.6-10), but there was no consistent pattern according to the time interval since last use. Separate analyses of choriocarcinoma and persistent mole yielded similar results, i.e., the relative risk estimates for oral contraceptive use were 2.2 (95% CI=0.8-6.4) and 1.8 (95% CI=1.0-3.0), respectively. Control for the number of sexual partners, which was independently associated with risk (P for trend = .05), did not materially change the results. CONCLUSIONS This study, the largest to date, indicates that long duration of oral contraceptive use before conception increases the risk of gestational trophoblastic tumors. These findings may provide clues to the pathogenesis of this rare disease. Changes in use of oral contraceptives are not warranted, however, because the incidence attributable to oral contraceptive use is very low.
Collapse
Affiliation(s)
- J R Palmer
- Slone Epidemiology Unit, Boston University School of Medicine, MA, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Affiliation(s)
- R S Berkowitz
- Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA 02115, USA
| | | |
Collapse
|